Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral)

Next Previous
Trial Profile

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Basiliximab; Corticosteroids; Ganciclovir; Methylprednisolone; Mycophenolic acid; Prednisone; Valganciclovir
  • Indications Cytomegalovirus infections; Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms EVERCMV

Most Recent Events

  • 06 Jan 2022 Results published in the American Journal of Transplantation
  • 01 Sep 2021 Primary endpoint (Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients.) has been met as per results presented at the 20th Congress of the European Society for Organ Transplantation
  • 01 Sep 2021 Results presented at the 20th Congress of the European Society for Organ Transplantation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top